Navigation Links
AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
Date:3/1/2012

IRVINE, Calif., March 1, 2012 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, today announced that it has initiated the first shipment of AHRO-001 Active Pharmaceutical Ingredient (API) to its research and development partner CardioNova, Ltd., a Russia based biotech company responsible for Phase 1 and 2 human clinical studies of AHRO-001. The clinical-grade material will be used to commence the toxicology studies conducted for Russian regulatory purposes.

"We are pleased to announce this first shipment, clearly a milestone for us in the development of AHRO-001 for use in upcoming human clinical studies," said AtheroNova CEO Thomas Gardner. "This is the highest purity ever achieved in AHRO-001 and is ready to be used in an advanced clinical setting for the first time. As we proceed through our clinical phases, we are extremely gratified to adhere to our aggressive development path and look forward to additional development milestones in the coming months."

"CardioNova is very excited to receive the first shipment," commented CardioNova CEO Andrey Boldyrev. "We are looking forward to starting the toxicology studies and initiating clinical studies in close cooperation with AtheroNova, who proves to be an ideal partner for this project. We believe that an effective partnership of our two companies will allow us to bring to market a novel drug that is much anticipated by doctors and patients all over the world."

About AHRO-001
AHRO-001 is AtheroNova's first novel application for the treatment and prevention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AHRO-001 uses certain natural compounds to regress atherosclerotic plaque deposits through a process known as delipidization. Delipidization dissolves plaques in artery walls, which are the
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AtheroNova Announces a New Board Member
2. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
3. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
4. AtheroNova Rodman & Renshaw Presentation Now Online at www.AtheroNova.com
5. GenVec Achieves Second Milestone in Collaboration
6. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
7. MedNet Solutions Achieves the Inc. 5000 List Five Years in a Row
8. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
9. New compact microspectrometer design achieves high resolution and wide bandwidth
10. Pharmacyclics Achieves $7 Million Development Milestone for HDAC Inhibitor, PCI-24781 / S 78454 with Servier
11. Leading Animal Stem Cell Developer MediVet-America Achieves Significant Business Growth Milestones in First Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... ... Sleepless nights will become obsolete as Luzi , a sophisticated smart ... June 23. Sound sleepers and the sleep deprived both will love Luzi for its ... integration of the Bluetooth speaker, alarm clock and ability to charge various devices, including ...
(Date:7/1/2015)...   Decision Resources Group finds that ... are its oral administration, alternative mechanism of action, ... rheumatologists. Otezla was the first oral therapy specifically ... psoriatic arthritis in the United States ... conventional oral treatments including disease-modifying antirheumatic drugs (DMARDs), ...
(Date:7/1/2015)... , July 1, 2015  Axovant Sciences ... focused on the treatment of dementia, today announced ... on July 22 at 5:45 p.m. EDT following ... Alzheimer,s Association International Conference 2015 (AAIC). ... , Dr. Lawrence Friedhoff , ...
(Date:7/1/2015)... Indianapolis, IN (PRWEB) , ... July 01, 2015 , ... ... the 2015 BIO International Convention in Philadelphia, PA. , The presentation took ... milestones and outlined the plans for the development of APX3330 for the treatment of ...
Breaking Biology Technology:Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2
... SyntheMed, Inc. (OTC Bulletin Board: SYMD ; ... stockholders approved the planned merger with Pathfinder, LLC at ... of 99% of the votes cast were voted in ... was previously announced and is described in detail in ...
... THOUSAND OAKS, Calif., Aug. 25, 2011 Emmy® and ... AMGN ) today launch Act 2 Reduce Fractures™, ... increased risk for fractures. Earlier this year, Danner was ... and wants to encourage women like her to educate ...
... 25, 2011 CBI, a division of Advanstar Communications, ... of the Tufts Center for the Study of Drug ... Medicine, is the keynote speaker at their Pharma/Bio Forum ... 26-27, 2011 at the Hyatt Harborside in Boston, MA. ...
Cached Biology Technology:SyntheMed, Inc. Announces Stockholder Approval of Planned Merger With Pathfinder, LLC 2SyntheMed, Inc. Announces Stockholder Approval of Planned Merger With Pathfinder, LLC 3Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 2Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 3Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 4Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 5Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 6Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 7Dr. Ken Kaitin, Tufts CSDD, Keynotes Preclinical Conference 2
(Date:6/23/2015)... BEACH GARDENS, Fla. , June 23, ... multi-factor identity management and authentication solutions, today announced ... Altus strong, multi-factor authentication solution.  The enhancements ... of use of the DigitalPersona Altus platform ... biometric reader compatibility. In today,s ...
(Date:6/17/2015)... , June 17, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Xiaomi, one of the ... ® ClearPad ® family of capacitive ... integrated circuits (DDICs) for its latest smartphones, the ... ClearPad for full in-cell display solutions and DDICs ...
(Date:6/16/2015)... Sweden , June 16, 2015 ... from previously communicated that it will amount to at least ... MSEK. Due to the rapid increase in market growth and ... the previously communicated guidance that revenue for 2015 will exceed ... will amount to approximately 2,200 MSEK. Due to ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
... in China,s carbon dioxide (CO2) emissions is far outpacing ... gases much more difficult, according to a new analysis ... UC San Diego. Previous estimates, including those used ... region that includes China will see a 2.5 to ...
... carbon dioxide (CO2) emissions is far outpacing previous estimates, ... more difficult, according to a new analysis by economists ... Diego. Previous estimates, including those used by the ... includes China will see a 2.5 to 5 percent ...
... has shed new light on a novel histone acetyltransferase ... a new acetyl functional group into histone proteins, a ... The findings were posted to the Web site ... appear in a future print edition of the journal. ...
Cached Biology News:New UC analysis shows alarming increase in expected growth of China's carbon dioxide emissions 2New UC analysis shows alarming increase in expected growth of China's carbon dioxide emissions 3Alarming growth in expected CO2 emissions in China, finds UC analysis 2Alarming growth in expected CO2 emissions in China, finds UC analysis 3Workman Lab characterizes novel regulator of chromosome function 2